Takeda Pharma (TKPYY) 25.6200 $TKPYY
The Short Heard 'Round The World - Part 1
Matthew Finston - at Seeking Alpha - 2 hrs 29 mins ago
CAJ: 32.37 (+0.08), TI: 11.01 (-0.24), DCM: 17.60 (+0.15), NOK: 8.02 (+0.05), SAP: 69.09 (unch), SNP: 80.13 (+0.33), SHPG: 239.82 (+6.11), TEF: 15.01 (+0.01), ALU: 3.89 (-0.03), HNP: 48.02 (-0.87), PUK: 49.47 (-0.72), AZN: 69.96 (+0.20), AI: 25.03 (-0.03), BABA: 89.05 (+1.95)
Jury Finds Actos Maker, Takeda, Responsible to Pay $2.3 Million in Actos Litigation, Parker Waichman LLP Comments
PRWeb - Fri Feb 13, 10:05AM CST
Parker Waichman LLP, a national law firm that has that is actively involved in Actos litigation and which has long been dedicated to protecting the rights of victims who have been injured by drugs and medical devices, is pleased with a recent jury verdict involving Actos. The Firm provides commentary on a recent jury decision ordering Takeda Pharmaceutical Co., to pay $2.3 million in a case involving Takeda Pharmaceuticals Inc.'s diabetes medication, Actos (pioglitazone). The Philadelphia jury found that Actos had been a significant cause of the plaintiff's bladder cancer and that his physician was not appropriately warned about the drug's risks. The Pennsylvania case is Kristufek v. Takeda Pharmaceuticals America Inc., Philadelphia Court of Common Pleas and the consolidated Actos case in Louisiana is In Re Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana (Lafayette).
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:18AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents.
BMRN: 100.76 (+1.98), SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:30PM CST
Orexigen Therapeutics (OREX) announced encouraging updates on its weight loss drug, Mysimba
BIIB: 391.66 (-0.45), OREX: 5.55 (+0.10), ALNY: 95.54 (+1.67)
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:30AM CST
AMAG Pharmaceuticals (AMAG) reported a fourth-quarter 2014 loss of 2 cents per share, narrower than the year-ago loss of 17 cents per share.
OPHT: 51.11 (+0.12), AMAG: 41.49 (+0.23), PRTA: 22.89 (+0.13)
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 34.64 (-0.23)
Interim results positive for Takeda blood cancer med
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:17AM CST
Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival
Business Wire - Tue Feb 10, 1:01AM CST
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial evaluating the safety and efficacy of ixazomib, the first oral proteasome inhibitor, conducted in patients with relapsed or refractory multiple myeloma (MM) achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis. In the trial, patients treated with investigational ixazomib plus lenalidomide and dexamethasone lived without their disease worsening for a significantly longer time compared to patients who received placebo plus lenalidomide/dexamethasone.
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Tue Jan 27, 10:31AM CST
The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), CBAY: 11.82 (unch), NVS: 102.20 (-0.17)
What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 9:50AM CST
AstraZeneca (AZN) announced that its Marketing Authorisation Application for the approval of lesinurad was accepted by the EMA.
JNJ: 99.62 (+1.18), AZN: 69.96 (+0.20)
Newly Approved Weight Loss Method Works by Tricking Your Brain
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 25, 11:02AM CST
You can lose weight through plenty of methods. Dieting. Exercising. Taking weight-loss drugs. Undergoing gastric bypass surgery. The newest way, though, just might be the coolest and most revolutionary way of all. Source: EnteroMedics, ...
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
The 2015 Calendar Of NASH Trial Catalysts: Takeda And Tobira
Clinically Sound Investor - at Seeking Alpha - Fri Jan 23, 11:43AM CST
RPTP: 9.05 (-0.40), RGDO: 1.17 (+0.02)
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 5.00 (-0.07), ISIS: 63.86 (-0.43), SRPT: 12.76 (+0.11)
AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 4:00PM CST
AMAG Pharmaceuticals (AMAG) provided preliminary results for the fourth quarter and full year 2014 as well as its 2015 financial guidance.
AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
Marketwired - Mon Jan 12, 7:02AM CST
CymaBay Therapeutics Inc. (NASDAQ: CBAY) today announced positive preliminary results from its clinical study of arhalofenate administered in combination with febuxostat (Uloric(TM), Takeda Pharmaceutical Company Limited). Arhalofenate is a once-daily, oral candidate for the treatment of gout with a unique dual mechanism of action which lowers serum uric acid (sUA) while also reducing the occurrence of gout flares.
CBAY: 11.82 (unch)
Prasco and Takeda Enter into Agreement to Market Authorized Generic of Colcrys® (colchicine, USP) in the United States
PR Newswire - Mon Jan 12, 7:00AM CST
Prasco Laboratories ("Prasco"
, Takeda Pharmaceutical Company Limited ("Takeda" , and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA" announced today that Prasco and TPUSA have entered into a distribution and supply agreement for the rights to distribute Colchicine Tablets, USP, the Authorized Generic (AG) version of Colcrys® (colchicine, USP) Tablets in the U.S. As a result of this partnership, Colchicine Tablets, USP will be the only colchicine product on the market that is therapeutically equivalent and automatically substitutable for prescriptions written for Colcrys Tablets, indicated for the prophylaxis and treatment of acute gout flares in adults, and the treatment of familial Mediterranean fever (FMF) in adults and children age four or older.
The Short Heard 'Round The World - Part 1
Matthew Finston - at Seeking Alpha - 2 hrs 29 mins ago
CAJ: 32.37 (+0.08), TI: 11.01 (-0.24), DCM: 17.60 (+0.15), NOK: 8.02 (+0.05), SAP: 69.09 (unch), SNP: 80.13 (+0.33), SHPG: 239.82 (+6.11), TEF: 15.01 (+0.01), ALU: 3.89 (-0.03), HNP: 48.02 (-0.87), PUK: 49.47 (-0.72), AZN: 69.96 (+0.20), AI: 25.03 (-0.03), BABA: 89.05 (+1.95)
Jury Finds Actos Maker, Takeda, Responsible to Pay $2.3 Million in Actos Litigation, Parker Waichman LLP Comments
PRWeb - Fri Feb 13, 10:05AM CST
Parker Waichman LLP, a national law firm that has that is actively involved in Actos litigation and which has long been dedicated to protecting the rights of victims who have been injured by drugs and medical devices, is pleased with a recent jury verdict involving Actos. The Firm provides commentary on a recent jury decision ordering Takeda Pharmaceutical Co., to pay $2.3 million in a case involving Takeda Pharmaceuticals Inc.'s diabetes medication, Actos (pioglitazone). The Philadelphia jury found that Actos had been a significant cause of the plaintiff's bladder cancer and that his physician was not appropriately warned about the drug's risks. The Pennsylvania case is Kristufek v. Takeda Pharmaceuticals America Inc., Philadelphia Court of Common Pleas and the consolidated Actos case in Louisiana is In Re Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana (Lafayette).
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:18AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents.
BMRN: 100.76 (+1.98), SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:30PM CST
Orexigen Therapeutics (OREX) announced encouraging updates on its weight loss drug, Mysimba
BIIB: 391.66 (-0.45), OREX: 5.55 (+0.10), ALNY: 95.54 (+1.67)
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:30AM CST
AMAG Pharmaceuticals (AMAG) reported a fourth-quarter 2014 loss of 2 cents per share, narrower than the year-ago loss of 17 cents per share.
OPHT: 51.11 (+0.12), AMAG: 41.49 (+0.23), PRTA: 22.89 (+0.13)
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 34.64 (-0.23)
Interim results positive for Takeda blood cancer med
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:17AM CST
Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival
Business Wire - Tue Feb 10, 1:01AM CST
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial evaluating the safety and efficacy of ixazomib, the first oral proteasome inhibitor, conducted in patients with relapsed or refractory multiple myeloma (MM) achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis. In the trial, patients treated with investigational ixazomib plus lenalidomide and dexamethasone lived without their disease worsening for a significantly longer time compared to patients who received placebo plus lenalidomide/dexamethasone.
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Tue Jan 27, 10:31AM CST
The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), CBAY: 11.82 (unch), NVS: 102.20 (-0.17)
What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 9:50AM CST
AstraZeneca (AZN) announced that its Marketing Authorisation Application for the approval of lesinurad was accepted by the EMA.
JNJ: 99.62 (+1.18), AZN: 69.96 (+0.20)
Newly Approved Weight Loss Method Works by Tricking Your Brain
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 25, 11:02AM CST
You can lose weight through plenty of methods. Dieting. Exercising. Taking weight-loss drugs. Undergoing gastric bypass surgery. The newest way, though, just might be the coolest and most revolutionary way of all. Source: EnteroMedics, ...
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
The 2015 Calendar Of NASH Trial Catalysts: Takeda And Tobira
Clinically Sound Investor - at Seeking Alpha - Fri Jan 23, 11:43AM CST
RPTP: 9.05 (-0.40), RGDO: 1.17 (+0.02)
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 5.00 (-0.07), ISIS: 63.86 (-0.43), SRPT: 12.76 (+0.11)
AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 4:00PM CST
AMAG Pharmaceuticals (AMAG) provided preliminary results for the fourth quarter and full year 2014 as well as its 2015 financial guidance.
AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
Marketwired - Mon Jan 12, 7:02AM CST
CymaBay Therapeutics Inc. (NASDAQ: CBAY) today announced positive preliminary results from its clinical study of arhalofenate administered in combination with febuxostat (Uloric(TM), Takeda Pharmaceutical Company Limited). Arhalofenate is a once-daily, oral candidate for the treatment of gout with a unique dual mechanism of action which lowers serum uric acid (sUA) while also reducing the occurrence of gout flares.
CBAY: 11.82 (unch)
Prasco and Takeda Enter into Agreement to Market Authorized Generic of Colcrys® (colchicine, USP) in the United States
PR Newswire - Mon Jan 12, 7:00AM CST
Prasco Laboratories ("Prasco"
, Takeda Pharmaceutical Company Limited ("Takeda" , and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA" announced today that Prasco and TPUSA have entered into a distribution and supply agreement for the rights to distribute Colchicine Tablets, USP, the Authorized Generic (AG) version of Colcrys® (colchicine, USP) Tablets in the U.S. As a result of this partnership, Colchicine Tablets, USP will be the only colchicine product on the market that is therapeutically equivalent and automatically substitutable for prescriptions written for Colcrys Tablets, indicated for the prophylaxis and treatment of acute gout flares in adults, and the treatment of familial Mediterranean fever (FMF) in adults and children age four or older. 
